Prolonged adjuvant XXXX chemotherapy improved survival of @entity5 after D2 gastrectomy.

@entity1 @entity901 @entity416 @entity3012 @entity5 @entity8566 @entity204 @entity356
GOALS: This study aims to investigate the safety and efficacy of prolonged adjuvant @entity416 chemotherapy on survival of @entity356 after D2 gastrectomy. BACKGROUND: Inadequate evidence is available on optimal duration of chemotherapy and the number of administered cycles is generally based on @entity1 responsiveness and individual tolerability as well as physician preferences. STUDY: We randomly assigned 307 @entity356 @entity1 after D2 gastrectomy between January 2006 and December 2010 to XELOX group and Prolonged group. XELOX consisted of a 2-h intravenous infusion of @entity901 130mg/mg on day 1 and oral @entity416 1000mg/m(2) twice daily on days 1-14 of a 3-week cycle for eight cycles in half a year. In Prolonged group, @entity1 underwent extra oral @entity416 1000mg/m(2) twice daily on days 1-14 of a 3-week cycle for eight cycles after eight cycles of XELOX. The disease-free survival and overall survival were compared. RESULTS: Significant differences were found in 3-year disease-free survival (Prolonged group 56.6%, XELOX group 48.4%, P=0.0357). Subgroup analysis by TNM staging showed that @entity1 with @entity5 in the Prolonged group had significantly higher DFS (50.00% vs 40.96, P=0.0178) and @entity3012 (71.95% vs 57.83, P=0.0230) than that of @entity1 in the XELOX group. No grade 4 adverse effects or treatment-related @entity204 were reported. More @entity1 in the Prolonged group experienced @entity8566 than in the XELOX group. CONCLUSIONS: Prolonged @entity416 chemotherapy prevents improves the prognosis of @entity1 with @entity5 after D2 gastrectomy.
